Clinical Trials Logo

Arthritis clinical trials

View clinical trials related to Arthritis.

Filter by:

NCT ID: NCT02917434 Completed - Obesity Clinical Trials

Effects of Weight-loss Treatment in Obese Patients With Psoriatic Arthritis

VIPsA
Start date: April 2016
Phase: N/A
Study type: Interventional

The study is an open intervention study with the aim to determine the effects of weight-loss treatment with Low-Energy liquid Diet (LED) on disease activity, quality of life and markers of the metabolic syndrome in patients with psoriatic arthritis and obesity.

NCT ID: NCT02915094 Completed - Clinical trials for Rheumatoid Arthritis

Kineret in the Treatment of Rheumatoid Arthritis

Start date: October 2012
Phase: N/A
Study type: Observational

Objective of the study is to gain knowledge about the administration of Kineret in patients with rheumatoid arthritis in the daily routine treatment and not in controlled trials. In the current survey, the investigation of the response rate of Kineret regarding the date of onset of action, the efficacy, as well as the tolerability and safety are of particular interest.

NCT ID: NCT02912221 Completed - Clinical trials for Arthritis, Rheumatoid

Stepping Up For Inflammatory Arthritis

SUFIA
Start date: April 24, 2017
Phase: N/A
Study type: Interventional

This study will examine the benefits of a monitored physical activity program for participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) using a wearable activity device (e.g.fitbit). The goals of this pilot study are to examine 1) whether an incentive is better than no incentive in maintaining an increased level of physical activity and 2) the benefits of physical activity on patient reported disease activity in inflammatory arthritis.

NCT ID: NCT02909998 Completed - Chronic Arthritis Clinical Trials

Biomarkers in Chronic Arthritis

Start date: October 2008
Phase: N/A
Study type: Observational

Use of genotyping for the optimization of treatment with biologics in chronic arthritis by looking for an association between certain alleles and response to treatment.

NCT ID: NCT02905175 Completed - Clinical trials for Rheumatoid Arthritis

Rheumatoid Arthritis Patients and Porphyromonas Gingivalis

Start date: January 13, 2016
Phase:
Study type: Observational

Rheumatoid arthritis (RA) is the most frequent joint inflammatory disease inducing joint destruction strongly correlated with anti-citrullinated protein antibodies citrullinated anti-peptide (ACPA). Precise RA etiology remained unclear with a described association between RA and periodontal disease. The missing link could be a gram-negative anaerobic bacterium called Porphyromonas gingivalis (P. gingivalis), which is heavily involved in periodontal disease and able to induce gingival citrullinated protein via an enzyme called peptidyl arginine deiminase (PAD). DNA of P. gingivalis was detected in synovial tissue and in peripheral blood mononuclear cell. To improve knowledge of P. gingivalis involvement in RA, the investigators will compare its effect on various cell type with comparison with another oral bacteria Provatella intermedia.

NCT ID: NCT02902562 Completed - Clinical trials for Rheumatoid Arthritis

Synovitis and Therapy Response in Inflammatory Arthritis With Contrast Enhanced Ultrasound

CEUS
Start date: August 31, 2016
Phase: N/A
Study type: Interventional

This study is about using contrast-enhanced ultrasound (CEUS) to assess the degree of synovitis (joint inflammation) in patients with inflammatory arthritis, such as rheumatoid arthritis, and whether it can be used for assessing a treatment response. The investigators hope to learn whether contrast enhanced ultrasounds are better than regular imaging techniques, such as MRI, when used to evaluate the response to disease modifying anti-rheumatic drug (DMARD) therapy in inflammatory arthritis.

NCT ID: NCT02900898 Completed - Inflammation Clinical Trials

Exercise and Mediterranean Diet on Body Composition, Disease Activity and Inflammatory Markers in Rheumatoid Arthritis

Start date: August 2016
Phase: N/A
Study type: Interventional

Rheumatoid arthritis (RA) is a chronic autoimmune disease with metabolic alterations due mainly by the liberation of catabolic cytokines leading to changes in body composition as rheumatoid cachexia. Dynamic exercise (DE) has demonstrated to improve muscular, strength and joint function as well as inflammatory process. Also, a diet focused on the consumption of certain fatty acids like the Mediterranean is recommended to reduce inflammation. The aim of this study is to assess the effect of a dynamic exercise program in combination with a Mediterranean diet in strength, joint mobility and disease activity in women with RA.

NCT ID: NCT02897817 Completed - Clinical trials for Rheumatoid Arthritis

Treatment Adherence to Injectable Methotrexate in Rheumatoid Arthritis

APRim
Start date: June 2016
Phase:
Study type: Observational

The aim of this study is to evaluate, at 6 months, the rate of patients whose adherence to injectable MTX remained strong or improved according to patient-reported outcome.

NCT ID: NCT02894047 Completed - Clinical trials for Arthritis, Rheumatoid

Study of the Influence of the Expression of the Calcium-sensitive Receptor (CaSR) by Monocytes in the Synovial Liquid on Structural Alterations in Patients Diagnosed With Rheumatoid Arthritis in the Previous Two Years

CASPER
Start date: July 2013
Phase: N/A
Study type: Observational

Rheumatoid arthritis (RA) is the most frequent form of chronic inflammatory rheumatism in adults. The erosive damage influences the functional prognosis in patients with RA. At present, there are no sufficiently sensitive and specific predictive markers of erosive damage.

NCT ID: NCT02889796 Completed - Clinical trials for Rheumatoid Arthritis

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

FINCH 1
Start date: August 30, 2016
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.